Normobaric Oxygen Therapy in Acute Ischemic Stroke Trial - Full Text View

Sponsor:	Massachusetts General Hospital
Collaborator:	National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by (Responsible Party):	Aneesh B. Singhal, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:	NCT00414726

Purpose

The purpose of this study is to compare the safety and efficacy of treating individuals with acute ischemic stroke with normobaric oxygen therapy (NBO, given within 9 hours of symptom onset), to standard medical treatment.

Condition	Intervention	Phase
Ischemic Stroke	Drug: NBO (Normobaric Oxygen) Drug: Room Air	Phase II

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	Clinical Trial of Normobaric Oxygen Therapy in Acute Ischemic Stroke

Resource links provided by NLM:

MedlinePlus related topics: Oxygen Therapy

U.S. FDA Resources

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:

Primary Safety Outcome Measure is a Comparison of the Change in National Institutes of Health Stroke Scale (NIHSS) Scores From Baseline to 24 Hours (After Therapy) in the Two Groups. [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]
The NIHSS score ranges from 0 (best score) to 42 (worst score).
Primary Efficacy Outcome Measure is a Comparison of the Change in National Institutes of Health Stroke Scale (NIHSS) Scores From Baseline to 4 Hours (During Therapy) in the Two Groups. [ Time Frame: 4 hours after starting treatment ] [ Designated as safety issue: No ]
The NIHSS score ranges from 0 (best score) to 42 (worst score).

Enrollment:	85
Study Start Date:	January 2007
Study Completion Date:	June 2009
Primary Completion Date:	June 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: NBO (Normobaric Oxygen) Oxygen, inhaled at 30-45L/min via a facemask for 8 hours	Drug: NBO (Normobaric Oxygen) High-flow oxygen delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours. Drug: Room Air Room Air delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
Placebo Comparator: Room Air Room Air, inhaled at 30-45L/min via a facemask for 8 hours	Drug: NBO (Normobaric Oxygen) High-flow oxygen delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours. Drug: Room Air Room Air delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.

Arms

Assigned Interventions

Active Comparator: NBO (Normobaric Oxygen)

Oxygen, inhaled at 30-45L/min via a facemask for 8 hours

Drug: NBO (Normobaric Oxygen)

High-flow oxygen delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.

Drug: Room Air

Room Air delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.

Placebo Comparator: Room Air

Room Air, inhaled at 30-45L/min via a facemask for 8 hours

Drug: NBO (Normobaric Oxygen)

High-flow oxygen delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.

Drug: Room Air

Room Air delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.

Detailed Description:

Stroke is the third leading cause of death and the leading cause of disability in the United States. Ischemic stroke is caused by a blockage of blood flow to one or more brain arteries, usually due to a blood clot. As a result there is a reduced supply of oxygen and other nutrients leading to permanent brain damage. Normobaric oxygen therapy (NBO, or high-flow oxygen delivered via a facemask) shows promise as a simple, widely accessible, low-cost therapy that can prevent stroke-related brain damage and extend the time window for administering the clot-busting drug t-PA (tissue plasminogen activator), which is the only acute stroke treatment approved by the Food and Drug Administration.

The primary goal of this trial is to compare the safety and therapeutic efficacy of NBO (started within 9 hours of symptom onset) to standard medical treatment with Room Air. We aim to enroll a total of 240 individuals with acute ischemic stroke less than 9 hours after symptom onset, at the Massachusetts General and Brigham and Women's Hospitals in Boston. Participants will be randomly selected to receive either room air (RA, control) or NBO (active treatment) at flow rates of 30-45L/min administered via a face mask for 8 hours. Neurological function scores and neuroimaging [magnetic resonance imaging (MRI) or computed tomography (CT) scans] will be obtained before, during, and after therapy until 90 days.

This study is part of the Specialized Program of Translational Research in Acute Stroke (SPOTRIAS), which allows researchers to enhance and initiate translational research that ultimately will benefit individuals with stroke.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age greater than or equal to 18 years.
Acute ischemic stroke in whom treatment can potentially be started within 9 hours after symptom onset. If the symptom onset time is unknown, the time of onset will be defined as the midpoint between the time when the subject was last seen neurologically intact, and when found to have a neurological deficit.
National Institutes of Health Stroke Scale (NIHSS) score 4 or greater.

Exclusion Criteria:

Patients being actively considered for intravenous or intra-arterial thrombolysis will be excluded.
Patients likely to have acute stroke intervention such as carotid endarterectomy or stent or angioplasty, hemicraniectomy, etc.
Rapidly improving neurological deficits (transient ischemic attack).
Known history of severe chronic obstructive pulmonary disease (Forced Expiratory Vital Capacity less than 1.0 or oxygen dependent).
More than 3 L/min oxygen required to maintain peripheral arterial oxygen saturation above 92%.
New York Heart Association Class III heart failure.
Endotracheal intubation prior to enrollment or impending need for artificial ventilation.
Coma (National Institutes of Health Stroke Scale item 1a score of 3).
Suspected seizure at or after onset of stroke, or a known active seizure disorder.
Blood glucose below 50 mg/dL or greater than 250 mg/dL prior to enrollment.
Concurrent severe non-stroke medical illness requiring admission to a non-neurological intensive care unit
Expected survival less than 90 days.
Any condition that might limit neurological assessment or follow-up in the opinion of the investigator.
Pre-menopausal women with a positive pregnancy blood test performed at admission.
Inability to obtain consent from the patient or legally authorized representative.
Active participation in another intervention study (e.g. investigational drug trial).
Proven alternate etiology for stroke-like symptoms.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00414726

Locations

United States, Massachusetts
Massachusetts General Hospital, ACC-729C
Boston, Massachusetts, United States, 02114
Brigham and Women's Hospital, 75 Francis Street
Boston, Massachusetts, United States, 02115

Sponsors and Collaborators

Massachusetts General Hospital

National Institute of Neurological Disorders and Stroke (NINDS)

Investigators

Principal Investigator:

Aneesh B Singhal, MD

Massachusetts General and Brigham & Women's Hospitals

More Information

Additional Information:

Specialized Program of Translational Research in Acute Stroke website This link exits the ClinicalTrials.gov site

Publications:

Singhal AB, Benner T, Roccatagliata L, Koroshetz WJ, Schaefer PW, Lo EH, Buonanno FS, Gonzalez RG, Sorensen AG. A pilot study of normobaric oxygen therapy in acute ischemic stroke. Stroke. 2005 Apr;36(4):797-802. Epub 2005 Mar 10.

Kim HY, Singhal AB, Lo EH. Normobaric hyperoxia extends the reperfusion window in focal cerebral ischemia. Ann Neurol. 2005 Apr;57(4):571-5.

Singhal AB, Dijkhuizen RM, Rosen BR, Lo EH. Normobaric hyperoxia reduces MRI diffusion abnormalities and infarct size in experimental stroke. Neurology. 2002 Mar 26;58(6):945-52.

Singhal AB, Ratai E, Benner T, Vangel M, Lee V, Koroshetz WJ, Schaefer PW, Sorensen AG, Gonzalez RG. Magnetic resonance spectroscopy study of oxygen therapy in ischemic stroke. Stroke. 2007 Oct;38(10):2851-4. Epub 2007 Aug 30.

Singhal AB. Oxygen therapy in stroke: past, present, and future. Int J Stroke. 2006 Nov;1(4):191-200. Review.

Fujiwara N, Murata Y, Arai K, Egi Y, Lu J, Wu O, Singhal AB, Lo EH. Combination therapy with normobaric oxygen (NBO) plus thrombolysis in experimental ischemic stroke. BMC Neurosci. 2009 Jul 15;10:79.

Responsible Party:	Aneesh B. Singhal, MD, Associate Professor of Neurology, Massachusetts General Hospital
ClinicalTrials.gov Identifier:	NCT00414726 History of Changes
Other Study ID Numbers:	R01NS051412, P50NS051343
Study First Received:	December 21, 2006
Results First Received:	July 1, 2010
Last Updated:	October 28, 2011
Health Authority:	United States: Food and Drug Administration

Keywords provided by Massachusetts General Hospital:

ischemic stroke
normobaric oxygen therapy

Additional relevant MeSH terms:

Ischemia
Stroke
Cerebral Infarction
Pathologic Processes
Cerebrovascular Disorders
Brain Diseases

Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Brain Infarction
Brain Ischemia

ClinicalTrials.gov processed this record on February 09, 2012